Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. (2022)
Attributed to:
Respiratory infections
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(22)00271-7
PubMed Identifier: 35550261
Publication URI: http://europepmc.org/abstract/MED/35550261
Type: Journal Article/Review
Volume: 22
Parent Publication: The Lancet. Infectious diseases
Issue: 8
ISSN: 1473-3099